172@29@17@102!~!172@29@0@53!~!|news|navneeteducation|results-NP01-6months.html!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
Moneycontrol
results
Jump to
15 Results Found
  • Natco Q3 PAT may dip 24% YoY to Rs. 165 cr: Sharekhan Jan 18, 2019 03:09 PM IST

    Natco Q3 PAT may dip 24% YoY to Rs. 165 cr: Sharekhan

    Net Sales are expected to decrease by 5 percent Y-o-Y (down 1.8 percent Q-o-Q) to Rs. 534 crore, according to Sharekhan.

  • Natco Pharma Q3 PAT may dip 30.3% YoY to Rs. 151.7 cr: ICICI Direct Jan 11, 2019 06:07 PM IST

    Natco Pharma Q3 PAT may dip 30.3% YoY to Rs. 151.7 cr: ICICI Direct

    Net Sales are expected to decrease by 4.9 percent Y-o-Y (down 1.6 percent Q-o-Q) to Rs. 534.7 crore, according to ICICI Direct.

  • Natco Q2 PAT seen up 78.6% YoY to Rs. 150 cr: Sharekhan Oct 17, 2018 11:28 AM IST

    Natco Q2 PAT seen up 78.6% YoY to Rs. 150 cr: Sharekhan

    Net Sales are expected to increase by 20 percent Y-o-Y (down 4.9 percent Q-o-Q) to Rs. 512 crore, according to Sharekhan.

  • Natco Pharma Q2 PAT seen up 118.2% YoY to Rs. 185 cr: ICICI Direct Oct 12, 2018 05:35 PM IST

    Natco Pharma Q2 PAT seen up 118.2% YoY to Rs. 185 cr: ICICI Direct

    Net Sales are expected to increase by 31.3 percent Y-o-Y (up 4 percent Q-o-Q) to Rs. 560.1 crore, according to ICICI Direct.

  • Natco Pharma Q4 PAT seen up 78.5% YoY to Rs. 315.3 cr: Edelweiss Apr 16, 2018 06:25 PM IST

    Natco Pharma Q4 PAT seen up 78.5% YoY to Rs. 315.3 cr: Edelweiss

    Net Sales are expected to increase by 29 percent Y-o-Y (up 30.5 percent Q-o-Q) to Rs. 745.1 crore, according to Edelweiss.

  • Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key Apr 12, 2018 05:53 PM IST

    Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

    Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

  • Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key Jan 18, 2018 08:36 AM IST

    Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

    As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

  • Natco Pharma Q4 PAT may dip 26.8% to Rs 156.1 cr: ICICI Securities Apr 17, 2017 01:51 PM IST

    Natco Pharma Q4 PAT may dip 26.8% to Rs 156.1 cr: ICICI Securities

    Net Sales are expected to decrease by 18.5 percent Q-o-Q (up 36 percent Y-o-Y) to Rs 553.4 crore, according to ICICI Securities. Natco Pharma to report net profit at 156.1 crore down 26.8% quarter-on-quarter.

  • Natco Pharma Q3 PAT seen up 6.1% to Rs 70.3 cr: ICICI Securities Jan 16, 2017 12:46 PM IST

    Natco Pharma Q3 PAT seen up 6.1% to Rs 70.3 cr: ICICI Securities

    Net Sales are expected to decrease by 1.8 percent Q-o-Q (up 66.4 percent Y-o-Y) to Rs 459.3 crore, according to ICICI Securities.

  • Pharma biz to drive Jubilant Life's future growth: Surajit Pal Aug 10, 2016 11:36 AM IST

    Pharma biz to drive Jubilant Life's future growth: Surajit Pal

    Jubilant Life Sciences working on reducing its debt through internal accruals against taking fresh loan will serve well for its future growth says Surajit Pal, Prabhudas Lilladher.

  • Natco Pharma Q1 PAT seen down by 24.1% at Rs 45.7 cr: Religare Jul 16, 2016 01:08 PM IST

    Natco Pharma Q1 PAT seen down by 24.1% at Rs 45.7 cr: Religare

    Sales are expected to decrease by 20.6 percent Q-o-Q (up 44.4 percent Y-o-Y) to Rs 323.0 crore, according to Religare Research.

  • Natco Pharma Q1 PAT seen down 34.1% to Rs 39.7 cr: Edelweiss Jul 14, 2016 06:19 PM IST

    Natco Pharma Q1 PAT seen down 34.1% to Rs 39.7 cr: Edelweiss

    Net Sales are expected to decrease by 29 percent Q-o-Q (up 29.1 percent Y-o-Y) to Rs 288.8 crore, according to Edelweiss

  • Pharma companies revenues to rise 12% in Q3: Anand Rathi Jan 03, 2014 05:34 PM IST

    Pharma companies revenues to rise 12% in Q3: Anand Rathi

    Pharma companies are likely to post 12 percent Y-o-Y revenue growth. However, excluding Wockhardt (FDA issues) and Fortis Healthcare (divestments), revenue growth is expected to be 19 percent Y-o-Y.

  • Patent win against Teva to boost revenues: Natco Pharma Nov 18, 2013 01:16 PM IST

    Patent win against Teva to boost revenues: Natco Pharma

    Bhaskar Narayana, Finance Director & CFO, Natco Pharma is confident of maintaining the current growth rate in terms of margins going forward.

  • See Rs 20-25cr in revenue/quarter from Lanzoprazol: Natco Feb 14, 2013 02:44 PM IST

    See Rs 20-25cr in revenue/quarter from Lanzoprazol: Natco

    Hyderabad-based Natco Pharma Limited, on December 21, received the approval from Food & Drug Administration (FDA) for marketing the prescription version of Lanzoprazole, CFO of the company Bhaskar Narayana told CNBC-TV18 in an interview.

Sections